Literature DB >> 2542561

New 1,4-dihydropyridine derivatives combining calcium antagonism and alpha-adrenolytic properties.

G Marciniak1, A Delgado, G Leclerc, J Velly, N Decker, J Schwartz.   

Abstract

A series of twelve 1,4-dihydropyridine derivatives incorporating an alpha-adrenergic moiety in one of the ester chains was synthesized. The compounds were evaluated for their calcium antagonist activities by the inhibition of [3H]nitrendipine binding and, in vitro, on pig coronary artery. Their alpha 1- and alpha 2-adrenolytic effects were assessed from their inhibition of [3H]prazosin and [3H]yohimbine binding and, in vitro, on rat aorta and guinea pig vas deferens. Compounds 6 and 9-11 displayed strong calcium antagonist activities, identical with that of nicardipine. The moderate alpha-adrenolytic properties observed were attributed to the presence of alpha-adrenergic moieties. The four chiral derivatives 6a (R,R), 6b (S,S), 6c (S,R), and 6d (R,S) with an N-methyl-N-(benzodioxanylmethyl)amino group on the ester chain were prepared and tested as done previously. Some structure-activity relationships are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542561     DOI: 10.1021/jm00126a042

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Intercepted-Knoevenagel condensation for the synthesis of unsymmetrical fused-tricyclic 4H-pyrans.

Authors:  Charles Shearer; Oriane Desaunay; Stephen Zorc; Alexis D Richaud; Shyam S Samanta; Nagalakshmi Jeedimalla; Stéphane P Roche
Journal:  Tetrahedron       Date:  2019-09-17       Impact factor: 2.457

2.  1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.

Authors:  Mauro Cataldi; Fiorentina Bruno
Journal:  Transl Med UniSa       Date:  2012-10-11

3.  Palladium-catalyzed tandem allylic substitution/cyclization and cascade hydrosilylated reduction: the influence of reaction parameters and hydrosilanes on the stereoselectivity.

Authors:  Peng-Wei Long; Jian-Xing Xu; Xing-Feng Bai; Zheng Xu; Zhan-Jiang Zheng; Ke-Fang Yang; Li Li; Li-Wen Xu
Journal:  RSC Adv       Date:  2018-06-22       Impact factor: 3.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.